Loading...

Major Indexes

Financial Summary


Array BioPharma Inc.

Array BioPharma Inc. (ARRY)

$46.57
17.69 (+61.25%)
Neutral
B+
Market Info
Financial Info
Financial Modelling
Symbol ARRY
Price 46.57$
Beta 1.44
Volume Avrg. 3.00M
Market Cap 9.24B
Shares (2018) 198,490.00K
Last Div 0
Dividend Yield -
DCF Unlevered -15.33 Strong Sell
DCF Levered -17.56 Strong Sell
ROE -67.03% Strong Sell
ROA -32.00% Strong Sell
Operating Margin -74.77% Strong Sell
Debt / Equity 109.50% Buy
P/E -22.03 Strong Sell
P/B 14.77 Strong Buy

Income Statement

Quarter data
Download ARRY income statement Download ARRY income statement Download ARRY income statement
Year 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Earnings Per Share Diluted -2.04-2.67-1.55-1.02-0.33-0.57-0.690.07-0.65-0.72-0.74
Net Profit Margin -3.34-5.12-1.44-0.78-0.28-0.89-2.030.18-0.67-0.77-0.85
Weighted Average Shares Outstanding 47.3147.8450.2255.45135.11135.11135.11136.68142.96163.21198.49
Revenue 28.8124.9853.8871.9085.1469.5842.0851.91137.88150.85173.77
Weighted Average Shares Outstanding (Diluted) 47.3147.8450.2255.4570.62107.79123.40141.69142.96163.21198.49
Gross Profit 7.445.1325.5642.9860.8739.50-3.897.52114.71115.46114.39
Dividend per Share -----------
Operating Income -98.49-102.45-64.05-36.77-11.05-39.54-75.623.29-82.21-102.08-129.93
Gross Margin 0.260.210.470.600.720.57-0.090.140.830.770.66
Income Tax Expense ----------2.30
EBIT Margin -3.21-3.84-1.07-0.41-0.07-0.44-1.570.25-0.54-0.61-0.70
Net Income -96.29-127.81-77.63-56.32-23.58-61.94-85.269.37-92.84-116.80-147.30
Cost of Revenue 21.3619.8628.3228.9224.2630.0845.9744.3923.1735.4059.37
Earnings Before Tax Margin -3.34-5.13-1.44-0.78-0.28-0.89-2.030.18-0.67-0.77-0.83
EBIT -98.49-102.45-64.05-36.77-11.05-39.54-75.623.29-82.21-102.08-129.93
EBITDA -92.39-95.84-57.71-29.16-5.97-30.72-65.8512.79-74.31-92.55-121.44
Profit Margin -3.34-5.12-1.44-0.78-0.28-0.89-2.030.18-0.67-0.77-0.85
Operating Expenses 127.30127.44117.93108.6796.18109.12117.70130.27220.09252.93303.69
Earnings Per Share Basic -2.04-2.67-1.55-1.02-0.33-0.57-0.690.07-0.65-0.72-0.74
Earnings before Tax -96.29-128.10-77.63-56.32-23.58-61.94-85.269.37-92.84-116.80-145.05
Interest Expense 1.9910.0215.7515.5111.6211.269.7210.2510.8712.3310.81

Balance Sheet Statement

Quarter data
Download ARRY balance shet statement Download ARRY balance sheet statement Download ARRY balance sheet statement
Year 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Short-term debt ----0.15----12.602.50
Other Assets -----------
Total current liabilities 34.4150.3077.9369.8175.9450.5852.7342.4252.4369.5595.93
Cash and cash equivalents 56.4533.2032.8548.1055.8060.7468.5955.6956.60125.93114.75
Long-term debt 2.251.951.722.3192.1199.02103.95107.28113.66121.3193.38
Cash and short-term investments 95.6940.50111.5164.0833.38108.24111.00178.33109.94234.32412.49
Total debt 35.3583.17112.8391.5492.2699.02103.95107.28113.66121.3195.88
Inventories -----------
Deferred revenue 5.9911.2352.4747.8742.3414.356.198.9512.8617.1612.35
Goodwill and Intangible Assets -----------
Total non-current liabilities 3.002.422.526.53117.94107.32112.04113.13154.40197.87144.69
Total non-current assets 69.4033.79100.0831.6814.9714.6817.387.1613.608.978.82
Total liabilities 90.64118.46197.93150.42193.88157.90164.77155.55206.83267.42240.62
Total assets 62.3250.1441.8818.81108.07135.99139.05198.21168.90279.14460.36
Other comprehensive income 39.92---484.84610.65692.08751.07763.32930.331,319.99
Short-term investments 39.247.3078.6615.9933.3847.5142.41122.6453.34108.39297.74
Property, Plant & Equipment Net 30.1626.5021.4115.7012.0610.058.165.056.688.137.13
Net Debt -21.0949.9779.9843.4492.2638.2835.3651.5957.06-4.63-18.87
Investments 78.4914.59157.3331.9733.8547.9743.05123.1353.94109.12298.66
Total shareholders equity 38.03-73.70-116.68-130.86-85.81-21.91-25.7242.65-37.9311.73219.74
Retained earnings (deficit) -----570.74-632.68-717.94-708.57-801.41-918.70-1,100.00
Long-term investments 39.247.3078.6615.990.470.470.640.500.600.730.92
Receivables -----9.605.436.3139.3031.2832.08
Payables 4.666.485.634.466.475.406.954.5710.158.6414.06
Total current assets 100.7544.92117.3070.5693.11121.31121.68191.05155.30270.18451.54

Cash Flow Statement

Quarter data
Download ARRY cash flow statement Download ARRY cash flow statement Download ARRY cash flow statement
Year 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Investing Cash Flow 50.7329.00-69.0674.07-18.72-16.362.48-58.0566.03-58.12-191.04
Free Cash Flow -45.57-92.9417.56-65.94-34.98-89.41-74.30-8.30-73.25-42.92-121.02
Depreciation & Amortization 6.106.616.347.625.088.839.769.507.909.538.49
Net cash flow / Change in cash 45.78-23.25-0.3615.257.704.947.86-12.900.9169.33-11.19
Effect of forex changes on cash -----------
Financing Cash Flow 40.7940.6951.157.1259.97108.3777.0650.944.97166.81299.63
Dividend payments -----------
Stock-based compensation 6.165.955.373.332.353.454.337.817.289.9619.11
Investment purchases -71.59-19.14-78.78-53.04-51.34-110.72-95.60-202.91-139.15-387.55-442.60
Acquisitions and disposals -----------
Capital Expenditure -0.17---1.442.342.612.513.163.521.23
Operating Cash Flow -45.74-92.9417.56-65.94-33.55-87.07-71.68-5.79-70.09-39.40-119.78

Retained Earning Schedule

Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Retained Earnings (Previous Year) ------571-633-718-709-801-919
Net Income -96-128-78-56-24-62-859-93-117-147
Stock Dividends 961287856-547-----0-34
Dividend Paid -----------
Retained Earnings -----571-633-718-709-801-919-1,100

PPE Schedule

Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Gross PPE 283026211612108578
Annual Depreciation 2-4-5-6-5-4-5-6-2-2-2
Capital Expenditure -0---1233341
Net PPE 30262116121085787

Intangible and Goodwill Schedule

Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Intangible and Goodwill (Previous Year) -----------
New Purchases -72-19-79-53-51-111-96-203-139-388-443
Intangible and Goodwill -----------

About


Ron Squarer
Healthcare
Biotechnology
NASDAQ Global Market

Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.